This observational work has analyzed the results of major trials such as PIONEER AF-PCI (rivaroxaban + DAPT vs. VKA + DAPT after PCI), RE-DUAL PCI (dabigatran + P2Y12 inhibitor vs. warfarin + DAPT after PCI), AUGUSTUS (apixaban or VKA + P2Y12 inhibitor with or without ASA after ACS or PCI), and ENTRUST-AF PCI (edoxaban + clopidogrel vs. VKA + DAPT after PCI) in which the authors analyzed the results of both elective and urgent patients undergoing a PCI. The gene discussed is P2RY12; the disease is atrial fibrillation.